AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome

Nature Reviews Drug Discovery

Volumn 3, Issue 4, 2004, Pages 340-351

  Ruderman, Neil ^a   Prentki, Marc ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; ADIPONECTIN; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; DIACYLGLYCEROL; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCEROLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LEPTIN; LIPID; MALONYL COENZYME A; METFORMIN; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; DIET THERAPY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; EXERCISE; FATTY ACID METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFECT; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 3843061592     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1344     Document Type: Review

References (165)

1. Reaven, G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
2. Ruderman, N., Chisholm, D., Pi-Sunyer, X. & Schneider, S. The metabolically obese, normal-weight individual revisited. Diabetes 47, 699-713 (1998).
3. Reaven, G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106, 286-288 (2002).
4. Kissebah, A. H. et al. Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 53, 254-260 (1982).
5. Nyholm, B. et al. Insulin resistance in relatives of NIDDM patients: the role of physical fitness and muscle metabolism. Diabetologia 39, 813-822 (1996).
6. Ruderman, N. B., Saha, A. K., Vavvas, D. & Witters, L. A. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 276, E1-E18 (1999).
7. McGarry, J. D. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51, 7-18 (2002).
8. Unger, R. H. Lipotoxic diseases. Annu. Rev. Med. 53, 319-336 (2002).
9. Prentki, M. & Corkey, B. E. Are the β-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45, 273-283 (1996).
10. Ryysy, L. et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49, 749-758 (2000).
11. Krssak, M. et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42, 113-116 (1999).
12. Jacob, S. et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48, 1113-1119 (1999).
13. Seppala-Lindroos, A. et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023-3028 (2002).
14. Lee, Y. et al. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc. Natl Acad. Sci. USA 91, 10878-10882 (1994).
15. Ohneda, M., Inman, L. R. & Unger, R. H. Caloric restriction in obese pre-diabetic rats prevents β-cell depletion, loss of β -cell GLUT 2 and glucose incompetence. Diabetologia 38, 173-179 (1995).
16. Higa, M. et al. Troglitazone prevents mitochondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats. Proc. Natl Acad. Sci. USA 96, 11513-11518 (1999).
17. Unger, R. H. & Orci, L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15, 312-321 (2001).
18. Ruderman, N. B. et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem. Soc. Trans. 31, 202-206 (2003).
19. Prentki M, J. E., El-Assaad W, Roduit R. Malonyl-CoA Signaling, Lipid Partitioning, and Glucolipotoxicity: Role in β-cell adaptation and failure in the etiology of diabetes. Diabetes 51, S405-S413 (2002).
20. Listenberger, L. L. et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl Acad. Sci. USA 100, 3077-3082 (2003).
21. McGarry, J. D. & Brown, N. F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244, 11-14 (1997).
22. Prentki, M. & Matschinsky, F. M. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol. Rev. 67, 1185-1248 (1987).
23. Corkey, B. E. et al. A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic β -cells. J. Biol. Chem. 264, 21608-21612 (1989).
24. Prentki, M. et al. Malony-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J. Biol. Chem. 267, 5802-6810 (1992).
25. Saha, A. K., Kurowski, T. G. & Ruderman, N. B. A malonyl-CoA fuel-sensing mechanism in muscle: effects of insulin, glucose, and denervation. Am. J. Physiol. 269, E283-E289 (1995).
26. Saha, A. K., Kurowski, T. G., Colca, J. R. & Ruderman, N. B. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacyglycerol. Am. J. Physiol. 267, E95-E101 (1994).
27. Hu, Z., Cha, S. H., Chohnan, S. & Lane, M. D. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc. Natl Acad. Sci. USA 100, 12624-12629 (2003).
28. Hardie, D. G. & Carling, D. The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur. J. Biochem. 246, 259-273 (1997).
29. Kemp, B. E. et al. AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31, 162-168 (2003).
30. Dagher, Z., Ruderman, N., Tornheim, K. & Ido, Y. Acute regulation of fatty acid oxidation and AMP-activated protein kinase in human umbilical vein endothelial cells. Circ. Res. 88, 1276-1282 (2001).
31. Itani, S. I. et al. Glucose autoregulates its uptake in skeletal muscle: involvement of AMP-activated protein kinase. Diabetes 52, 1635-1640 (2003).
32. Fryer, L. G., Parbu-Patel, A. & Carling, D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232 (2002).
33. Hawley, S. A., Gadalla, A. E., Olsen, G. S. & Hardie, D. G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420-2425 (2002).
34. Woods, A. et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13, 2004-2008 (2003).
35. Saha, A. K. et al. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside. J. Biol. Chem. 275, 24279-24283 (2000).
36. Muoio, D. M., Seefeld, K., Witters, L. A. & Coleman, R. A. AMP-activated knees reciprocally regulates triacylglycerol synthesis and fatty and oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem. J. 338, 783-791 (1999).
37. Ferre, P., Azzout-Marniche, D. & Foufelle, F. AMP-activated protein kinase and hepatic genes involved in glucose metabolism. Biochem. Soc. Trans. 31, 220-223 (2003).
38. Winder, W. W. et al. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. 88, 2219-2226 (2000).
39. Rutter, G. A., DaSilvaXavier, G. & Leclerc, I. Roles of 5′AMP-activated protein kinase in mammalian glucose homeostasis. Biochem. J. 375, 1-16 (2003).
40. Zhou, M., Lin, B. Z., Coughlin, S., Vallega, G. & Pilch, P. F. UCP-3 expression in skeletal muscle: effects of exercise, hypoxia, and AMP-activated protein kinase. Am. J. Physiol. Endocrinol. Metab. 279, E622-E629 (2000).
41. Pedersen, S. B., Lund, S., Buhl, E. S. & Richelsen, B. Insulin and contraction directly stimulate UCP2 and UCP3 mRNA expression in rat skeletal muscle in vitro. Biochem. Biophys. Res. Commun. 283, 19-25 (2001).
42. Zheng, D. et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J. Appl. Physiol. 91, 1073-1083 (2001).
43. Leff, T. AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochem. Soc. Trans. 31, 224-247 (2003).
44. Barthels, A., Schmoll, D., Kruger, K. D., Roth, R. A. & Joost, H. G. Regulation of the forkhead transcription factor FKHR (FOXO1a) by glucose starvation and AICAR, an activator of AMP-activated protein kinase. Endocrinology 143, 3183-3186 (2002).
45. Leclerc, I. et al. Hepatocyte nuclear factor-4α involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 50, 1515-1521 (2001).
46. Terada, S. et al. Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochem. Biophys. Res. Commun. 296, 350-354 (2002).
47. Suwa, M., Nakano, H. & Kumagai, S. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol. 95, 960-968 (2003).
48. Randle, P., Garland, P. B., Hales, C. N. & Newsholme, E. A. The glucose fatty-acid cycyel its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet 1, 785-789 (1963).
49. Randle, P. J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14, 263-283 (1998).
50. Boden, G. et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J. Clin. Invest. 88, 960-966 (1991).
51. Heydrick, S. J., Ruderman, N. B., Kurowski, T. G., Adams, H. B. & Chen, K. S. Enhanced stimulation of diacylglycerol and lipid synthesis by insulin in denervated muscle. Altered protein kinase C activity and possible link to insulin resistance. Diabetes 40, 1707-1711 (1991).
52. Lin, Y. et al. Alterations of nPKC distribution, but normal Akt/PKB activation in denervated rat soleus muscle. Am. J. Physiol. Endocrinol. Metab. 283, E318-E325 (2002).
53. Considine, R. V. et al. Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J. Clin. Invest. 95, 2938-2944 (1995).
54. Itani, S. I., Ruderman, N. B., Schmieder, F. & Boden, G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκBα. Diabetes 51, 2005-2011 (2002).
55. Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176 (2000).
56. Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293, 1673-1677 (2001).
57. Hundal, R. S. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321-1326 (2002).
58. Goodpaster, B. H., He, J., Watkins, S. & Kelley, D. E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86, 5755-5761 (2001).
59. Kraegen, E. W. et al. Insulin resistance induced by glucose infusion is associated temporally with reduced muscle and liver AMPK activty. Diabetes 52, A330 (2003).
60. Laybutt, D. R. et al. Muscle lipid accumulation and protein kinase C activation in the insulin-resisant chronically glucose-infused rat. Am. J. Physiol. 277, E1070-E1076 (1999).
61. Iglesias, M. A. et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51, 2886-2894 (2002).
62. Oakes, N. D. et al. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 46, 2022-2028 (1997).
63. Mu, J., Brozinick, J. T., Jr., Valladares, O., Bucan, M. & Birnbaum, M. J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 7, 1085-1094 (2001).
64. Viollet, B. et al. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111, 91-98 (2003).
65. Lingohr, M. K., Buettner, R. & Rhodes, C. J. Pancreatic β-cell growth and survival - a role in obesity-linked type 2 diabetes? Trends Mol. Med. 8, 375-384 (2002).
66. Poitout, V. & Robertson, R. P. Minireview: Secondary β-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143, 339-342 (2002).
67. Porte, D., Jr. Banting lecture 1990. β-cells in type II diabetes mellitus. Diabetes 40, 166-180 (1991).
68. Pick, A. et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47, 358-364 (1998).
69. Butler, A. E. et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110 (2003).
70. Chen, S. et al. More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic β-cell signaling. Diabetes 43, 878-883 (1994).
71. Mulder, H. et al. Overexpression of a modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no impact on insulin secretion in INS-1-derived (832/13) β-cells. J. Biol. Chem. 276, 6479-6484 (2001).
72. Roduit, R. et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-α gene in the pancreatic β-cell. J. Biol. Chem. 275, 35799-35806 (2000).
73. Schuit, F. et al. Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in β-cells. J. Biol. Chem. 272, 18572-18579 (1997).
74. da Silva Xavier, G. et al. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371, 761-774 (2003).
75. Salt, I. P., Johnson, G., Ashcroft, S. J. & Hardie, D. G. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic β-cells, and may regulate insulin release. Biochem. J. 335, 533-539 (1998).
76. Brun, T., Roche, E., Kim, K. H. & Prentki, M. Glucose regulates acetyl-CoA carboxylase gene expression in a pancreatic β -cell line (INS-1). J. Biol. Chem. 268, 18905-18911 (1993).
77. Roche, E. et al. Long-term exposure of β-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes 47, 1086-1094 (1998).
78. Andreolas, C. et al. Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 β-cells. Diabetes 51, 2536-2545 (2002).
79. El-Assaad, W. et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death. Endocrinology 144, 4154-4163 (2003).
80. Ido, Y., Carling, D. & Ruderman, N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51, 159-167 (2002).
81. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
82. Buchanan, T. A. et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51, 2796-2803 (2002).
83. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
84. Steinberg, H. O. & Baron, A. D. Vascular function, insulin resistance and fatty acids. Diabetologia 45, 623-634 (2002).
85. Chen, Z. P. et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 443, 285-289 (1999).
86. Ido, Y. et al. The AMP-kinase (AMPK) activator, AICAR, inhibits the increase in oxidative stress induced by hyperglycemia and palmitate. Diabetes 51, A396 (2002).
87. Yu, A. S., Keeffe, E. B. Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord 2, 11-19 (2002).
88. Neuschwander-Tetri, B. A. & Caldwell, S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202-1219 (2003).
89. Koteish, A. & Diehl, A. M. Animal models of steatosis. Semin. Liver Dis. 21, 89-104 (2001).
90. Green, R. M. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 38, 14-17 (2003).
91. Lam, T. K. et al. Free fatty acid-induced hepatic insulin resistance a potential role for protein kinase C-delta. Am. J. Physiol. Endocrinol. Metab. 283, E682-E691 (2002).
92. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
93. Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. & Goldstein, J. L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73-76 (1999).
94. Xu, A., Wang, Y. et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J. Clin. Invest. 112, 91-100 (2003).
95. Neuschwander-Tetri, B. A. et al. Improved Nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38, 1008-1017 (2003).
96. Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med. 8, 1288-1295 (2002).
97. Tomas, E. et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl Acad. Sci. USA 99, 16309-16313 (2002).
98. Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells. Eur. J. Biochem. 229, 558-565 (1995).
99. Park, H. et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J. Biol. Chem. 277, 32571-32577 (2002).
100. Moule, S. K. & Denton, R. M. The activation of p38 MAPK by the β-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett. 439, 287-290 (1998).
101. Wu, X. et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52, 1355-1363 (2003).
102. Ruderman, N., Saha, A. & Kraegen, E. W. Malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 144, 5161-5171 (2003).
103. Richter, E. A., Garetto, L. P., Goodman, M. N. & Ruderman, N. B. Muscle glucose metabolism following exercise in the rat: increased sensitivity to insulin. J. Clin. Invest. 69, 785-793 (1982).
104. Skerrett, P. J. & Manson, J. E. in Handbook of Exercise in Diabetes 2nd edn (eds Ruderman, N., Devlin, J. R., Schneider, S. H. & Kriska, A.) 158-182 (American Diabetes Association, Alexandria, 2002).
105. Pan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20, 537-544 (1997).
106. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
107. Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98, 2005-2010 (2001).
108. Rajala, M. W., Scherer, P. E. The adipocyte - at the crossroads of energy homeostasis, inflammation and atherosclerosis. Endocrinology 144, 3765-3773 (2003).
109. Maeda, N. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Med. 8, 731-737 (2002).
110. Okamoto, Y. et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767-2770 (2002).
111. Yamauchi, T. et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278, 2461-2468 (2003).
112. Matsuzawa, Y., Funahashi, T. & Nakamura, T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann. NY Acad. Sci. 892, 146-154 (1999).
113. Ido, Y., Yagihashi, N., Cacicedo, J. M., Ruderman, N. B. AMP-kinase activation prevents TNF-α induced ICAM expression by inhibiting NF-κB transactivation but not by inhibiting their translocation or DNA-binding. Diabetes 51, A458 (2002).
114. Goldfine, A. B. & Kahn, C. R. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 362, 1431-1432 (2003).
115. Minokoshi, Y. et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343 (2002).
116. Olefsky, J. M. Treatment of insulin resistance with peroxisome proliferator-activated receptor-γ agonists. J. Clin. Invest. 106, 467-472 (2000).
117. Mayerson, A. B. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797-802 (2002).
118. Hsueh, W. A. & Law, R. The central role of fat and effect of peroxisome proliferator-activated receptor-γ on progression of insulin resistance and cardiovascular disease. Am. J. Cardiol. 92, 3J-9J (2003).
119. Haffner, S. M. Insulin resistance, inflammation, and the prediabetic state. Am. J. Cardiol. 92, 18J-26J (2003).
120. Saha, A., Ye, J., Assiti, M., Kraegen, E., Ruderman, N. B. & Arilucca, P. R. Pioglitazone treatment activates AMP-activated protein kinase (AMPK) in both liver and adipose tissue in the rat. Biochem. Biophys. Res. Commun. 314, 580-585 (2004).
121. Yu, J. G. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51, 2968-2974 (2002).
122. Tanaka, T. et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid β -oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad. Sci. USA 100, 15924-15929 (2003).
123. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001).
124. Musi, N. et al. Metformin increases AMP-activated protein kinase, activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51, 2074-2081 (2002).
125. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865 (1998).
126. Evans, J. L., Goldfine, I. D., Maddux, B. A. & Grodsky G. M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52, 1-8 (2003).
127. Inoguchi, T. et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49, 1939-1945 (2000).
128. Summers, S. A., Garza, L. A., Zhou, H. & Bimbaum, M. J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18, 5457-5464 (1998).
129. Blazquez, C., Geelen, M. J., Velasco, G. & Guzman, M. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett. 489, 149-153 (2001).
130. Cacicedo, J. M., Yagihashi, N., Adachi, T., Ruderman, N. R., and Yasudo, I. Palmitate-induced cultured bovine retinal pericyte (BRP) apoptosis is inhibited by activating AMP-activated protein kinase (AMPK), by expression of Cu, Zn superoxide dismutase (SOD1) and dominant negative mutant IκB. Diabetes 52, A199 (2003).
131. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activy in muscle. J. Biol. Chem. 277, 50230-50236 (2002).
132. Marshall, S. The hexosamine signaling pathway: a new road to drug discovery. Curr. Opin. Endocrinol. Diabetes 9, 160-167 (2002).
133. Veerababu, G. et al. Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes 49, 02070-2078 (2000).
134. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267-273 (2003).
135. Patti, M. E. et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc. Natl Acad. Sci. USA 100, 8466-8471 (2003).
136. Kelley, D. E., He, J., Menshikova, E. V. & Ritov, V. B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51, 2944-2950 (2002).
137. Petersen, K. F. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140-1142 (2003).
138. Schneider, S. H., Khachadurian, A. K., Amorosa, L. F., Clemow, L. & Ruderman, N. B. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellittus. Diabetes Care 15, 1800-1810 (1992).
139. Diehl, A. M. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G1-G5 (2002).
140. Maestre, I. et al. Mitochondrial dysfunction is involved in apoptosis induced by serum withdrawal and fatty acids in the β-cell line INS-1. Endocrinology 144, 335-345 (2003).
141. Zong, H. et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in resonse to chronic energy deprivation. Proc. Natl Acad. Sci. USA 99, 15983-15987 (2002).
142. Reitman, M. L. Metabolic lessons from genetically lean mice. Annu. Rev. Nutr. 22, 459-482 (2002).
143. Gavrilova, O. et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271-278 (2000).
144. Haque, W. A., Shimomura, I., Matsuzawa, Y. & Garg, A. serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab. 87, 2395 (2002).
145. Arioglu, E. et al. Leptin replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570-578 (2002).
146. Petersen, K. F. et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350 (2002).
147. Sbraccia, P. et al. Rosiglitazone treatment improves insulin sensitivity in lipodystrophic patients with mandibuloacral diplasia. Diabetes 52, A1 (2003).
148. Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 7, 941-946 (2001).
149. Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. & Wakil, S. J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616 (2001).
150. Winder, W. W. & Hardie, D. G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277, E1-E10 (1999).
151. Bavenholm, P. V., Pigon, J., Saha, A. K., Ruderman, N. B. & Efendic, S. Fatty acid oxidation and the regulation of malonyl-CoA in human muscle. Diabetes 49, 1078-1083 (2000).
152. Dean, D. et al. Exercise diminishes the activity of acetyl-CoA carboxylase in human muscle. Diabetes 49, 1295-1300 (2000).
153. Chien, D., Dean, D., Saha, A. K., Flatt, J. P. & Ruderman, N. B. Malonyl-CoA content and fatty acid oxidation in rat muscle and liver in vivo. Am. J. Physiol. Endocrinol. Metab. 279, E259-E265 (2000).
154. Vavvas, D. et al. Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. J. Biol. Chem. 272, 13255-13261 (1997).
155. Winder, W. W. & Hardie, D. G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 270, E299-E304 (1996).
156. Habinowski, S. A. et al. Malonyl-CoA decarboxylase is not a substrate of AMP-activated protein kinase in rat fast-twitch skeletal muscle or an islet cell line. Arch. Biochem. Biophys. 396, 71-79 (2001).
157. Hardie, D. G., Scott, J. W., Pan, D. A. & Hudson, E. R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546, 113-120 (2003).
158. Hawley S. A. et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003).
159. Ruderman, N. B. et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta. Physiol. Scand. 178, 435-442 (2003).
160. Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y. & Takahashi, H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52, 581-587 (2003).
161. Eto, K. Y. T., Matsui, J., Terauchi, Y., Noda, M. & Kadowaki, T. Genetic manipulations of fatty acid metabolism in β-cells are associated with dysregulated insulin secretion. Diabetes 51, S414-S420 (2002).
162. Wang, H. et al. The transcription factor SREBP-1c is instrumental in the development of β-cell dysfunction. J. Biol. Chem. 278, 16622-16629 (2003).
163. Lupi, R. et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 51, S134-S137 (2002).
164. Sreenan, S., Sturis, J., Pugh, W., Burant, C. F. & Polonsky, K. S. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am. J. Physiol. 271, E742-E747 (1996).
165. Roduit, R. et al. A role for the malonyl-CoA/long chain acyl-CoA pathway of lipid signalling in the regulation of insulin secretion in response to both fuel and non-fuel stimuli. Diabetes (in the press).